Checking for pancreatic cancer typically involves a combination of imaging scans, blood tests, and a tissue biopsy, usually in that order. There is no single test that confirms the diagnosis on its own. The process often begins after symptoms like unexplained weight loss, jaundice, or new-onset abdominal pain prompt a doctor to take a closer look at the pancreas.
Only about 15% of pancreatic cancers are caught while still confined to the pancreas, largely because the organ sits deep in the abdomen and early-stage disease rarely causes noticeable symptoms. Understanding how each diagnostic step works can help you know what to expect if your doctor suspects a problem.
Imaging Scans: The First Look
The most common starting point is a CT scan, specifically a high-resolution, contrast-enhanced version sometimes called a “pancreatic protocol” CT. You receive an injection of contrast dye, and the scan is timed to capture images during the moment when the pancreas absorbs the most dye. This creates a sharp contrast between normal pancreatic tissue and any tumor, which typically absorbs less dye and appears darker on the images. CT scans are good at showing tumors, revealing whether they’ve spread to nearby blood vessels, and helping surgeons assess whether a tumor can be removed.
CT does have blind spots. Tumors smaller than about half a centimeter can be difficult to detect, and the scan sometimes struggles to distinguish a cancerous mass from inflammation caused by chronic pancreatitis. A well-defined mass with clear borders tends to point toward cancer, while inflammation often looks more diffuse. But imaging signs that were once considered reliable indicators of cancer, like simultaneous swelling of the main pancreatic duct and the bile duct, can also appear in non-cancerous conditions.
MRI scans are used as a complement or alternative, particularly when there’s a need to evaluate cysts on the pancreas or to get a better look at the pancreatic and bile ducts. A specialized form of MRI called MRCP (magnetic resonance cholangiopancreatography) produces detailed images of these ducts without requiring any instruments to enter the body. In studies comparing MRCP to older, more invasive duct imaging techniques, MRCP achieved a diagnostic accuracy of about 92% with a 98% success rate for producing usable images.
PET scans are occasionally used as well, though they play a smaller role. They’re more helpful for detecting whether cancer has spread to distant parts of the body than for finding the original tumor.
Blood Tests and CA 19-9
A blood test measuring a protein called CA 19-9 is commonly ordered when pancreatic cancer is suspected. Pancreatic tumors often release this protein into the bloodstream, and elevated levels can support a diagnosis. However, CA 19-9 is not reliable enough to be used on its own for screening or diagnosis. Healthy people can have elevated levels, and conditions like bile duct blockages or liver disease can push the number up without any cancer being present.
On the other side, some people simply don’t produce CA 19-9, even when they have pancreatic cancer. For these individuals, the test provides no useful information at all. Because of these limitations, doctors use CA 19-9 alongside imaging and biopsy results rather than as a standalone tool. Where CA 19-9 proves most useful is after diagnosis: tracking whether levels rise or fall during treatment gives doctors a way to gauge how well therapy is working.
Endoscopic Ultrasound and Biopsy
If imaging reveals a suspicious mass, the next step is usually an endoscopic ultrasound, or EUS. A thin, flexible tube with a tiny ultrasound probe on its tip is passed through your mouth, down your throat, and into your stomach. From there, the probe can get extremely close to the pancreas and produce detailed images that CT and MRI sometimes miss.
The real value of EUS is that it allows a biopsy at the same time. While the ultrasound probe is in position, a fine needle is passed through the tube and into the mass to collect tissue or fluid samples. This technique, first performed in 1991, has an estimated sensitivity of 85% to 93% for detecting pancreatic cancer. The procedure typically involves about five needle passes into the mass. Doctors aim for different areas of the lesion with each pass, avoiding the very center (which may be necrotic and yield poor samples) and the outer edges (which tend to contain scar tissue and inflammation rather than cancer cells).
If a pathologist is present during the procedure, they can examine samples immediately and let the doctor know whether enough diagnostic material has been collected. When that isn’t available, the standard approach of five passes provides the best balance between getting a good sample and minimizing risk.
What Recovery Looks Like
An EUS-guided biopsy is generally safe, with the main risks being minor bleeding and infection. Most people go home the same day. In cases where a more extensive surgical biopsy is needed, such as a laparoscopy (small keyhole incisions in the abdomen), the cuts typically heal within about a week. A laparotomy, which involves a larger incision, usually requires a hospital stay of a few days.
Genetic Testing After Diagnosis
If pancreatic cancer is confirmed, genetic testing is now a standard recommendation. A blood or saliva sample is analyzed for inherited DNA changes that may have contributed to the cancer’s development. This matters for two reasons. First, certain genetic mutations can open the door to targeted treatments that work differently from standard chemotherapy. Second, the results may reveal that close family members carry an elevated risk and could benefit from surveillance.
People with a family history of pancreatic cancer or known inherited genetic changes linked to higher cancer risk may qualify for regular screening before any symptoms appear. Research from the National Cancer Institute suggests that this kind of surveillance in high-risk individuals may help catch cancers earlier, when treatment has a better chance of success.
Why There’s No Routine Screening Test
Unlike breast, colon, or cervical cancer, there is no widely recommended screening test for pancreatic cancer in the general population. CA 19-9 produces too many false positives and false negatives. Imaging is expensive and impractical at scale. Researchers have been working on blood-based tests that detect cancer DNA fragments circulating in the bloodstream, sometimes called liquid biopsies. Early results presented at cancer research conferences have shown promise for detecting pancreatic cancer in its earliest stages, but none of these tests have received FDA approval for pancreatic cancer screening, and they need further study before they could be used in routine care.
For now, the most important thing you can do is pay attention to new, persistent symptoms that don’t have an obvious explanation, particularly if you have a family history of pancreatic cancer or carry known genetic risk factors. Unexplained weight loss, new-onset diabetes in someone over 50, persistent back or abdominal pain, and jaundice are the symptoms most likely to prompt the diagnostic workup described above.